Ehsan Malek
About
Ehsan Malek is a scholar working on Hematology, Oncology and Molecular Biology.
According to data from OpenAlex, Ehsan Malek has authored 113 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Hematology, 46 papers in Oncology and 38 papers in Molecular Biology. Recurrent topics in Ehsan Malek's work include Multiple Myeloma Research and Treatments (62 papers), Protein Degradation and Inhibitors (17 papers) and Hematopoietic Stem Cell Transplantation (14 papers). Ehsan Malek is often cited by papers focused on Multiple Myeloma Research and Treatments (62 papers), Protein Degradation and Inhibitors (17 papers) and Hematopoietic Stem Cell Transplantation (14 papers). Ehsan Malek collaborates with scholars based in United States, Canada and South Korea. Ehsan Malek's co-authors include James J. Driscoll, Sajjeev Jagannathan, James J. Ignatz-Hoover, Byung‐Gyu Kim, Sung Hee Choi, Marcos de Lima, Nikhil Vad, Muthulekha Swamydas, Kenneth C. Anderson and James H. Finke and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Ehsan Malek
98 papers receiving 1.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ehsan Malek United States | 15 | 744 | 538 | 397 | 261 | 245 | 113 | 1.3k | ||
| Edgar Jost Germany | 23 | 1.0k 1.3× | 392 0.7× | 551 1.4× | 183 0.7× | 314 1.3× | 100 | 1.8k | ||
| Liang Hu China | 19 | 669 0.9× | 309 0.6× | 193 0.5× | 321 1.2× | 127 0.5× | 31 | 1.2k | ||
| Claire Seedhouse United Kingdom | 25 | 1.1k 1.5× | 548 1.0× | 547 1.4× | 246 0.9× | 118 0.5× | 62 | 1.7k | ||
| Carsten Grüllich Germany | 25 | 557 0.7× | 493 0.9× | 258 0.6× | 188 0.7× | 264 1.1× | 90 | 1.5k | ||
| Shudao Xiong China | 22 | 614 0.8× | 503 0.9× | 155 0.4× | 469 1.8× | 427 1.7× | 49 | 1.4k | ||
| Saleh Rachidi United States | 16 | 454 0.6× | 544 1.0× | 104 0.3× | 164 0.6× | 305 1.2× | 27 | 1.2k | ||
| Attaya Suvannasankha United States | 24 | 850 1.1× | 966 1.8× | 875 2.2× | 100 0.4× | 301 1.2× | 76 | 1.7k | ||
| Jay Yang United States | 18 | 810 1.1× | 281 0.5× | 318 0.8× | 156 0.6× | 85 0.3× | 103 | 1.3k | ||
| Benjamin D. Hedley Canada | 16 | 464 0.6× | 544 1.0× | 190 0.5× | 228 0.9× | 85 0.3× | 40 | 1.1k |
Countries citing papers authored by Ehsan Malek
Since
Specialization
Citations
This map shows the geographic impact of Ehsan Malek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ehsan Malek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ehsan Malek more than expected).
Fields of papers citing papers by Ehsan Malek
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ehsan Malek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ehsan Malek. The network helps show where Ehsan Malek may publish in the future.
Co-authorship network of co-authors of Ehsan Malek
This figure shows the co-authorship network connecting the top 25 collaborators of Ehsan Malek. A scholar is included among the top collaborators of Ehsan Malek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ehsan Malek. Ehsan Malek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dholaria, Bhagirathbhai, Mehmet H. Kocoglu, Leyla Shune, et al.. (2025). A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort (Arm C). Transplantation and Cellular Therapy. 31(2). S38–S38.
2.
Ignatz-Hoover, James J., et al.. (2025). Melphalan 140 mg/m2 is Safe and Effective for Frail and Older Multiple Myeloma Patients With Comparable Rates of Minimal Residual Disease Negativity. Clinical Lymphoma Myeloma & Leukemia. 25(7). e443–e451.e3.
3.
Rana, Priyanka S., James J. Ignatz-Hoover, Byung‐Gyu Kim, et al.. (2024). HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity. Cancer Research Communications. 4(6). 1517–1532.
4.
Rana, Priyanka S., James J. Ignatz-Hoover, Amber L. Mosley, et al.. (2024). Immunoproteasome Activation Expands the MHC Class I Immunopeptidome, Unmasks Neoantigens, and Enhances T-cell Anti-Myeloma Activity. Molecular Cancer Therapeutics. 23(12). 1743–1760.
5.
Malek, Ehsan, Priyanka S. Rana, Muthulekha Swamydas, et al.. (2024). The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial. Nature Communications. 15(1). 7388–7388.
6.
Malek, Ehsan, Leland Metheny, Pingfu Fu, et al.. (2024). Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. Transplantation and Cellular Therapy. 30(7). 698.e1–698.e10.
7.
Malek, Ehsan, et al.. (2024). P-137 Optimizing Feature Selection for Large Language Models in AI-Assisted Clinical Assessment of Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S119–S120.
8.
Driscoll, James J., Priyanka S. Rana, Ehsan Malek, & James J. Ignatz-Hoover. (2023). An Immunoproteasome Activator That Increases MHC Class I Antigen Presentation to Enhance Anti-Tumor Immunity. Blood. 142(Supplement 1). 3642–3642.
9.
Ahmed, Nausheen, Patricio Rojas, Fahrettin Covut, et al.. (2021). Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria. Bone Marrow Transplantation. 56(6). 1458–1461.
10.
Diamond, Akiva, Kirsten M Boughan, Brenda Cooper, et al.. (2021). Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates. Clinical Lymphoma Myeloma & Leukemia. 21(11). 799–804.
11.
Fox, Robert M., Jane Reese, Paolo F. Caimi, et al.. (2020). Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant. Blood. 136(Supplement 1). 35–37.
12.
Kundrapu, Sirisha, Stanton L. Gerson, James J. Driscoll, et al.. (2019). Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(5). e213–e220.
13.
Kim, Byung‐Gyu, Sung Hee Choi, Zhenghong Lee, et al.. (2018). Vactosertib, a TGF-ß Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors. Blood. 132(Supplement 1). 1918–1918.
14.
Covut, Fahrettin, Divya Gupta, Najla El Jurdi, et al.. (2018). Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 19(2). 73–82.
15.
Malek, Ehsan, Vinita Gupta, Richard J. Creger, et al.. (2018). Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. Leukemia & lymphoma. 59(8). 1905–1912.
16.
Gallogly, Molly, Paolo F. Caimi, Michael Craig, et al.. (2017). A Phase II Study of Midostaurin and 5-Azacitidine for Elderly Patients with Acute Myeloid Leukemia. Blood. 130. 1332–1332.
17.
Driscoll, James J., et al.. (2017). Eosinophils Upregulate PD-L1 and PD-L2 Expression to Enhance the Immunosuppressive Microenvironment in Multiple Myeloma. Blood. 130. 4417–4417.
18.
Siegel, David, Gary J. Schiller, Kevin Song, et al.. (2017). Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed. Blood. 130. 1812–1812.
19.
Sundaram, Suchitra, Benjamin Tomlinson, Richard J. Creger, et al.. (2017). Early Cardiovascular Toxicity with Treatment of Follicular Lymphoma Is Associated with Shorter Overall Survival. Blood. 130. 2776–2776.
20.
Malek, Ehsan, et al.. (2017). Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle. Frontiers in Oncology. 7. 287–287.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Edgar Jost Breakdown of academic impact, for papers by Liang Hu Breakdown of academic impact, for papers by Claire Seedhouse Breakdown of academic impact, for papers by Carsten Grüllich Breakdown of academic impact, for papers by Shudao Xiong Breakdown of academic impact, for papers by Saleh Rachidi Breakdown of academic impact, for papers by Attaya Suvannasankha Breakdown of academic impact, for papers by Jay Yang Breakdown of academic impact, for papers by Benjamin D. Hedley